Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Applied Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on February 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 18, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding its clinical trial protocols, which created a false impression of compliance with good clinical practices [5]. - It is claimed that the company's failure to adhere to trial protocols posed a severe risk of rejection of trial data by the U.S. Food and Drug Administration (FDA) during the New Drug Application process [5].

Core Viewpoint - A class action securities lawsuit has been filed against Applied Therapeutics, Inc. due to alleged securities fraud affecting investors between January 3, 2024, and December 2, 2024 [1] Group 1: Case Details - On November 27, 2024, Applied Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [2] - Following the CRL announcement, the stock price of Applied Therapeutics dropped from $10.21 per share on November 26, 2024, to $8.57 on November 27, 2024, and further declined to $2.03 on November 29, 2024, and $1.75 on December 2, 2024, marking a total decline of over 80% [2] - After disclosing a "warning letter" from the FDA regarding clinical trial issues on December 2, 2024, the stock price fell further to $1.69 on December 3, 2024, and continued to decline to $1.38 on December 4, 2024, and $1.29 on December 5, 2024 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 18, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who acquired Applied Therapeutics securities during the specified Class Period [1]. - The lead plaintiff deadline for the lawsuit is set for February 18, 2025 [1][3]. - The complaint alleges that the defendants made false or misleading statements and failed to disclose that Applied Therapeutics was not following trial protocols and good clinical practices, which posed a significant risk of FDA rejection of trial data [2]. Group 2: Lead Plaintiff Process - Investors in Applied Therapeutics can seek to be appointed as lead plaintiff representatives by the deadline of February 18, 2025, or choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and others from fraud and negligence by businesses [4].

Core Viewpoint - The news highlights a class action lawsuit against Applied Therapeutics, Inc. due to significant stock price declines following the issuance of a Complete Response Letter (CRL) from the FDA regarding its lead drug candidate, govorestat [2][3]. Group 1: Company Overview - Applied Therapeutics, Inc. is facing legal action from shareholders who purchased shares during the class period from January 3, 2024, to December 2, 2024 [2]. - The company’s stock price experienced a dramatic decline of over 80%, dropping from $10.21 per share on November 26, 2024, to $1.75 per share by December 2, 2024 [2]. Group 2: Regulatory Issues - On November 27, 2024, Applied Therapeutics announced it received a CRL from the FDA, indicating deficiencies in the clinical application of its New Drug Application (NDA) for govorestat [2]. - Following the CRL announcement, the company disclosed a "warning letter" from the FDA on December 2, 2024, which further impacted investor confidence and stock price [2]. Group 3: Shareholder Actions - Shareholders are encouraged to register for the class action lawsuit by February 18, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3].

Group 1 - The Rosen Law Firm is reminding purchasers of Applied Therapeutics, Inc. securities of the lead plaintiff deadline on February 18, 2025, for a class action lawsuit [1] - Investors who purchased securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding its clinical trial protocols, which created a risk of FDA rejection of trial data [5] - The firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the legal field [4]

Core Viewpoint - A securities class action lawsuit has been filed against Applied Therapeutics, Inc. for alleged misconduct related to its drug candidate, govorestat, during the Class Period from January 3, 2024, to December 2, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York [1]. - The lead plaintiff deadline for investors is set for February 18, 2025 [1][4]. - The complaint alleges that Applied Therapeutics made false or misleading statements and failed to disclose non-compliance with trial protocols, risking FDA rejection of trial data [3]. Group 2: Investor Information - Investors who suffered losses can seek to be appointed as lead plaintiffs or remain absent class members [4]. - The lead plaintiff represents the interests of all class members and selects counsel for the litigation [4]. - Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact them for more information [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Applied Therapeutics, Inc. due to allegations of securities law violations related to misleading statements and undisclosed adverse facts concerning the company's clinical trials and regulatory submissions [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in Applied Therapeutics to discuss their legal options [1]. - A federal securities class action has been filed against Applied Therapeutics, with a deadline of February 18, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false statements and failed to disclose significant issues regarding the Phase III INSPIRE trial, which misled investors [4]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the New Drug Application for govorestat, Applied Therapeutics' stock price fell by $1.64 per share, or 16.06%, closing at $8.57 on November 27, 2024 [5]. - After the FDA issued a Warning Letter indicating that the company was aware of significant issues with the govorestat NDA, the stock price dropped by $0.31 per share, or 18.34%, closing at $1.38 on December 4, 2024 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Applied Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on February 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by February 18, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Applied Therapeutics made false and misleading statements regarding their clinical trial protocols, which created a false impression of compliance with good clinical practices [5]. - It is claimed that the company's failure to adhere to proper trial protocols posed a severe risk of FDA rejection of trial data in a New Drug Application [5].

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=127301&from=3 CLASS P ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...